Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

Smart Share Global IPO: Surviving in a Competitive Market

Tuya IPO Trading Update: Recent Drop in Stock Price Offers a Good Entry Point

JD Health: Strong Earnings but Regulatory Environment Remains a Concern

Tencent Music Announces US$1bn Buyback After Shares Dip Double-Digit

JD Health IPO Trading Update: Be Ready to Buy if It Drops Post Index Inclusion

Zhihu IPO Valuation: Attractive at the Lower End of the IPO Pricing

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Bottom-Up

JD Health International  / Equity Bottom-Up

China’s largest online healthcare platform and retail pharmacy <a href="https://www.smartkarma.com/entities/jd-health-international-inc" target="_blank" data-smartkarma-citation="entities:29677:1" rel="noopener">JD Health (6618 HK)</a>  reported its maiden earnings post its IPO in December 2020. The company reported its 2H2020 and full-year results on Monday (29th March) after market which saw revenues increasing 78.8% YoY during full-year 2020. For 2H2020, JD Health’s revenues grew 81.2% YoY compared to a 76% YoY increase during 1H2020.Read our previous insights on JD Health's IPO:<a href="https://www.smartkarma.com/insights/jd-health-ipo-trading-update-be-ready-to-buy-if-it-drops-post-index-inclusion" target="_blank" data-smartkarma-citation="insights:46543" rel="noopener">JD Health IPO Trading Update: Be Ready to Buy if It Drops Post Index Inclusion</a> <a href="https://www.smartkarma.com/insights/jd-health-ipo-attractive-even-at-high-end-on-cheapness-and-gearing-to-healthcare-transformation" target="_blank" data-smartkarma-citation="insights:45699" rel="noopener">JD Health IPO: Attractive Even at High End on Cheapness and Gearing to Healthcare Transformation</a> <a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-peer-comparison-reveals-jd-health-s-financials-are-stronger-than-competition" target="_blank" data-smartkarma-citation="insights:44876" rel="noopener">JD Health Pre-IPO: Peer Comparison Reveals JD Health’s Financials Are Stronger than Competition</a> <a href="https://www.smartkarma.com/insights/jd-health-pre-ipo-poised-to-benefit-from-structural-changes-in-healthcare-in-china-and-the-pandemic" target="_blank" data-smartkarma-citation="insights:44220" rel="noopener">JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic</a>

China’s largest online healthcare platform and retail pharmacy JD Health (6618 HK)  reported its maiden earnings post its IPO in December 2020. The company reported its 2H2020 and full-year results on Monday (29th March) after market which saw revenues increasing 78.8% YoY during full-year 2020. For 2H2020, JD Health’s revenues grew 81.2% YoY compared to a 76% YoY increase during 1H2020.Read our previous insights on JD Health's IPO:JD Health IPO Trading Update: Be Ready to Buy if It Drops Post Index Inclusion JD Health IPO: Attractive Even at High End on Cheapness and Gearing to Healthcare Transformation JD Health Pre-IPO: Peer Comparison Reveals JD Health’s Financials Are Stronger than Competition JD Health Pre-IPO: Poised to Benefit from Structural Changes in Healthcare in China and the Pandemic 

JD Health 2020 Results: Strong Top Line Growth; Slight Decline in Margins Is Less of a Concern